Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Inks Another Orkambi Reimbursement Deal After France Says Yes

Executive Summary

The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.

You may also be interested in...



Another Ebola Vaccine Among New Filings At EMA

The European Medicines Agency has received 11 new marketing authorization applications, including three for orphan products from Vertex, MYR Pharmaceuticals and AstraZeneca.

At Last: Vertex Strikes CF Deal In England

After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.

Vertex Strikes Spanish Payment-For-Results CF Deal

Vertex has struck a reimbursement deal in Spain for Orkambi and hopes that it will also make progress in England where a new proposal has been made by the company.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141269

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel